In 2015, the Food and Drug Administration (FDA) approved three new therapies for MM: an oral proteasome inhibitor, ixazomib; along with two monoclonal antibodies against CD38 and SLAMF7, daratumumab and elotuzumab, respectively. Here, SLAMF7 is linked to Miyoshi myopathy.